Study of DP303c Injection in Patients With Advanced or Metastatic Gastric Cancer
Status:
Not yet recruiting
Trial end date:
2024-12-01
Target enrollment:
Participant gender:
Summary
This study is an open-label, multicenter, phase II study to evaluate the efficacy and safety
of DP303c injection in patients with HER2-positive advanced or metastatic gastric cancer.